| Public | NASDAQ:AMRS |
| Raised | |
| Post IPO Valuation |
| Website | amyrisbiotech.com |
| Category | CleanTech |
| Phone | (510) 450-0761 |
| Employees | |
| Description | Renewable Fuels |
| Draths Corporation, 11/11 |
| TOTAL | $309M |
| FUNDING TOTAL | $309M |
| Series A, 10/06 Khosla Ventures Kleiner Perkins Caufield & Byers TPG Growth | $20M |
| Series B, 9/07 DAG Ventures Khosla Ventures Kleiner Perkins Caufield & Byers TPG Growth | $70M |
| Series B, 8/08 DAG Ventures Khosla Ventures Kleiner Perkins Caufield & Byers TPG Growth | $21M |
| Series C, 10/09 Kleiner Perkins Caufield & Byers Khosla Ventures TPG Growth Votorantim Novos Negocios | $41.8M |
| Grant, 12/09 | $24.3M |
| Series D, 7/10 Temasek | $47.8M |
| Venture Round, 2/12 | $83.7M |
Amyris Biotechnologies creates renewable products, focusing on fuels and chemicals. The company plans to enter the market by 2011.
The company is developing renewable fuels that reduce lifecycle (GHG) emissions 80%. The fuel source is special in that it is compatible with current gasoline engines, and can be distributed with existing petroleum infrastructure.
Amyris is also developing semi-synthetic artemisinin, a key ingredient in first-line malaria treatments, in hopes of creating a complementary source of non-seasonal, high-quality, affordable artemisinin. This source would supplement the current botanical supply, offering millions of people infected with malaria the chance to gain consistent and reliable access to lower-cost, life-saving Artemisinin-based Combination Therapies (ACTs).
Lastly, Amyris produces environmentally friendly chemicals for a variety of consumer products and industrial applications currently dependent on petrochemical components.
